Multivariable analysis
| . | Adjusted SHR . | 95% CI . | P value . |
|---|---|---|---|
| Neutrophil engraftment* | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.97 | 0.59-1.61 | .905 |
| DSA 10 000-20 000 MFI | 0.68 | 0.24-1.93 | .468 |
| DSA >20 000 MFI | 0.36 | 0.11-0.99 | .048 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 0.92 | 0.37-2.25 | .859 |
| Persistent C1q positive | 0.33 | 0.09-0.99 | .049 |
| Platelet engraftment* | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.81 | 0.44-1.46 | .478 |
| DSA 10 000-20 000 MFI | 0.48 | 0.20-1.16 | .103 |
| DSA >20 000 MFI | 0.34 | 0.13-0.98 | .047 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 0.63 | 0.27-1.46 | .284 |
| Persistent C1q positive | 0.36 | 0.22-0.97 | .042 |
| Non-relapse mortality* | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.33 | 0.10-2.66 | .299 |
| DSA 10 000-20 000 MFI | 0.48 | 0.12-4.31 | .516 |
| DSA >20 000 MFI | 2.35 | 1.54-6.05 | .033 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | NA | NA | NA |
| Persistent C1q positive | 4.00 | 1.14-11.01 | .030 |
| Relapse | |||
| Model 1: impact of DSA level* | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 2.48 | 0.82-7.54 | .109 |
| DSA 10 000-20 000 MFI | 1.81 | 0.38-8.58 | .455 |
| DSA >20 000 MFI | 2.61 | 0.59-9.53 | .204 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 2.11 | 0.58-6.73 | .367 |
| Persistent C1q positive | 0.48 | 0.15-4.95 | .538 |
| Overall survival† | Adjusted HR | ||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.81 | 0.24-2.69 | .741 |
| DSA 10 000-20 000 MFI | 0.76 | 0.18-3.24 | .718 |
| DSA >20 000 MFI | 4.09 | 1.45-8.90 | .010 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 0.84 | 0.20-3.53 | .812 |
| Persistent C1q positive | 5.82 | 2.15-11.69 | .001 |
| Progression-free survival† | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 1.06 | 0.38-2.96 | .917 |
| DSA 10 000-20 000 MFI | 1.13 | 0.34-3.73 | .835 |
| DSA >20 000 MFI | 4.58 | 1.58-11.28 | .005 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 1.30 | 0.40-4.25 | .657 |
| Persistent C1q positive | 4.56 | 1.71-11.20 | .002 |
| . | Adjusted SHR . | 95% CI . | P value . |
|---|---|---|---|
| Neutrophil engraftment* | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.97 | 0.59-1.61 | .905 |
| DSA 10 000-20 000 MFI | 0.68 | 0.24-1.93 | .468 |
| DSA >20 000 MFI | 0.36 | 0.11-0.99 | .048 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 0.92 | 0.37-2.25 | .859 |
| Persistent C1q positive | 0.33 | 0.09-0.99 | .049 |
| Platelet engraftment* | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.81 | 0.44-1.46 | .478 |
| DSA 10 000-20 000 MFI | 0.48 | 0.20-1.16 | .103 |
| DSA >20 000 MFI | 0.34 | 0.13-0.98 | .047 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 0.63 | 0.27-1.46 | .284 |
| Persistent C1q positive | 0.36 | 0.22-0.97 | .042 |
| Non-relapse mortality* | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.33 | 0.10-2.66 | .299 |
| DSA 10 000-20 000 MFI | 0.48 | 0.12-4.31 | .516 |
| DSA >20 000 MFI | 2.35 | 1.54-6.05 | .033 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | NA | NA | NA |
| Persistent C1q positive | 4.00 | 1.14-11.01 | .030 |
| Relapse | |||
| Model 1: impact of DSA level* | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 2.48 | 0.82-7.54 | .109 |
| DSA 10 000-20 000 MFI | 1.81 | 0.38-8.58 | .455 |
| DSA >20 000 MFI | 2.61 | 0.59-9.53 | .204 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 2.11 | 0.58-6.73 | .367 |
| Persistent C1q positive | 0.48 | 0.15-4.95 | .538 |
| Overall survival† | Adjusted HR | ||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 0.81 | 0.24-2.69 | .741 |
| DSA 10 000-20 000 MFI | 0.76 | 0.18-3.24 | .718 |
| DSA >20 000 MFI | 4.09 | 1.45-8.90 | .010 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 0.84 | 0.20-3.53 | .812 |
| Persistent C1q positive | 5.82 | 2.15-11.69 | .001 |
| Progression-free survival† | |||
| Model 1: impact of DSA level | |||
| No DSA | Ref | ||
| DSA <10 000 MFI | 1.06 | 0.38-2.96 | .917 |
| DSA 10 000-20 000 MFI | 1.13 | 0.34-3.73 | .835 |
| DSA >20 000 MFI | 4.58 | 1.58-11.28 | .005 |
| Model 2: impact of C1q status after desensitization | |||
| No DSA | Ref | ||
| C1q positive to negative | 1.30 | 0.40-4.25 | .657 |
| Persistent C1q positive | 4.56 | 1.71-11.20 | .002 |
Impacts of covariates on outcomes of interest are not presented.
Abbreviations are explained in Table 2.
Subdistribution hazards regression model adjusted for age (continuous), sex, ABO mismatch, donor-recipient relation, DRI-R, conditioning regimen intensity, stem cell source, and HCT-CI.
Cox proportional hazards regression model adjusted for age (continuous), sex, ABO mismatch, donor-recipient relation, DRI-R, conditioning regimen intensity, stem cell source, and HCT-CI.